BioBusiness

Biotech drug manufacturers' emails may have been hacked by individuals with sophisticated investment banking skills, according to a report from the New York Times.

Merck announced an agreement with NewLink Genetics to acquire exclusive rights to its experimental Ebola vaccine, rVSV-EBOV, for $50 million.

Despite recent changes in corporate tax law, Ireland remains a valuable and attractive partner in the development and manufacture of biopharmaceuticals.

Approximately 40% of total global growth will come from specialty medications, according to a new report from the IMS Institute for Healthcare Informatics.

Biopharma continues to adopt single-use technologies, but also seeks more innovation and improvements in products.

Dual sourcing is one of many possible solutions to securing the supply chain.

M&A transactions accounted for nearly $15 billion more this year than for the same period a year ago.

The authors take a look at some of the recent developments in the German pharmaceutical market.

The authors take a look at the past and future impact of the Indian Pharmacopoeia Commission.

AAPS supports graduate-level programs impacted by cutbacks in funding and resources.

GSK is found guilty of offering bribes to doctors and is fined $489 million.

A dynamic market, industry consolidation, and demand fluctuations lead to a mixed picture of pricing results.

Trends in real estate and facility clusters give insight into the state of the biopharmaceutical industry.

Chinese healthcare reforms may be a double-edged sword for foreign companies.

Data analytic strategies can help companies capitalize on personalized medicine.

New International Council on Biotechnology Associations advocates biotechnology growth.

Gene therapy, immune-oncology, and digital healthcare technologies offer investors promise for innovation investments.

Is there potential for growth in Brazil's phytotherapic drug market?

The National Institutes of Health and the National Science Foundation set up biomedical innovation and business program.

Protecting intellectual property rights is vital to biopharmaceutical innovation.

Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.

Biopharma companies should not overlook India's growing market.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

Life-sciences companies continue upward momentum in 2014.